Introduction:68Ga-PSMA-11 is considered the gold standard in detection of micro and oligometastases in advanced prostate cancer, being used for therapeutic planning, as well as, potentially, for evaluating response to treatment. The development of ready-to-use lyophilized kit of PSMA-11 adds quality and safety to the routine use of this radiopharmaceutical and represents a pharmacotechnical challenge as it must preserve the integrity and specificity of the ligand. Methods: PSMA-11 kit formulation was proposed, considering radiolabeling parameters and the preservation of the peptide during the lyophilization process, using mannitol as an excipient. Critical temperature characterization studies were carried out using DSC equipment and the freeze-drying process was developed. The direct radiolabeling conditions were evaluated and standardized using 68Ge/68Ga generator eluate from two different manufacturers (ITG and Eckert & Ziegler). The radiochemical purity was evaluated by TLC and HPLC. Biological evaluation was carried out with lyophilized PSMA-11 to demonstrate the integrity of the peptide and preservation of biological activity after the lyophilization process. Results:Based on critical temperature characterization studies, the freeze-drying cycle was designed to reach a freezing temperature of around ？40？C and primary drying at 2？C. Using 20 mg of mannitol, an intact and elegant lyophilized cake was obtained. PSMA-11 lyophilized kit was directly labeled with 68Ga eluate from 68Ge/68Ga GMP generators (ITG and Eckert & Ziegler) resulting in % RP > 95% at pH 4.0 to 4.5. The results obtained from in vitro and in vivo biological competition studies confirmed the preservation of PSMA-11 affinity for the receptor after lyophilization. Conclusion: A lyophilized formulation (Kit) of PSMA-11 was successfully obtained, which preserved the integrity and biological activity of the peptide and guaranteed radiolabeling efficiency.
References
[1]
James, N.D., Tannock, I., N’Dow, J., Feng, F., Gillessen, S., Ali, S.A., et al. (2024) The Lancet Commission on Prostate Cancer: Planning for the Surge in Cases. The Lancet, 403, 1683-1722. https://doi.org/10.1016/s0140-6736(24)00651-2
[2]
Privé, B.M., Janssen, M.J.R., van Oort, I.M., Muselaers, C.H.J., Jonker, M.A., de Groot, M., et al. (2020) Lutetium-177-PSMA-I&T as Metastases Directed Therapy in Oligometastatic Hormone Sensitive Prostate Cancer, a Randomized Controlled Trial. BMC Cancer, 20, Article No. 884. https://doi.org/10.1186/s12885-020-07386-z
[3]
Mokaleng, B.B., Ebenhan, T., Ramesh, S., Govender, T., Kruger, H.G., Parboosing, R., et al. (2015) Synthesis,68Ga-Radiolabeling, and Preliminary invivoAssessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent. BioMed Research International, 2015, Article ID: 284354. https://doi.org/10.1155/2015/284354
[4]
Ruigrok, E.A.M., van Vliet, N., Dalm, S.U., de Blois, E., van Gent, D.C., Haeck, J., et al. (2020) Extensive Preclinical Evaluation of Lutetium-177-Labeled PSMA-Specific Tracers for Prostate Cancer Radionuclide Therapy. European Journal of Nuclear Medicine and Molecular Imaging, 48, 1339-1350. https://doi.org/10.1007/s00259-020-05057-6
[5]
Hennrich, U. and Eder, M. (2021) [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals, 14, Article 713. https://doi.org/10.3390/ph14080713
[6]
Satpati, D., Shinto, A., Kamaleshwaran, K.K., Sane, S. and Banerjee, S. (2016) Convenient Preparation of [68Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy. Molecular Imaging and Biology, 18, 420-427. https://doi.org/10.1007/s11307-016-0943-z
[7]
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W., Wängler, C., Mier, W., et al. (2012) 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry, 23, 688-697. https://doi.org/10.1021/bc200279b
[8]
Eder, M., Schäfer, M., Bauder-Wüst, U., Haberkorn, U., Eisenhut, M. and Kopka, K. (2014) Preclinical Evaluation of a Bispecific Low-Molecular Heterodimer Targeting Both PSMA and GRPR for Improved PET Imaging and Therapy of Prostate Cancer. The Prostate, 74, 659-668. https://doi.org/10.1002/pros.22784
[9]
Mercanoglu, G., Zilbeyaz, K. and Arslan, N. (2023) Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical. Current Radiopharmaceuticals, 16, 38-43. https://doi.org/10.2174/1874471015666220721095938
[10]
Kleynhans, J., Rubow, S., le Roux, J., Marjanovic-Painter, B., Zeevaart, J.R. and Ebenhan, T. (2020) Production of [68Ga]Ga-PSMA: Comparing a Manual Kit-Based Method with a Module-Based Automated Synthesis Approach. Journal of Labelled Compounds and Radiopharmaceuticals, 63, 553-563. https://doi.org/10.1002/jlcr.3879
[11]
Beheshti, M., Paymani, Z., Brilhante, J., Geinitz, H., Gehring, D., Leopoldseder, T., et al. (2018) Optimal Time-Point for 68Ga-PSMA-11 PET/CT Imaging in Assessment of Prostate Cancer: Feasibility of Sterile Cold-Kit Tracer Preparation? European Journal of Nuclear Medicine and Molecular Imaging, 45, 1188-1196. https://doi.org/10.1007/s00259-018-3970-y
[12]
Lepareur, N. (2022) Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals? Frontiers in Medicine, 9, Article 812050. https://doi.org/10.3389/fmed.2022.812050
[13]
Meisenheimer, M., Kürpig, S., Essler, M. and Eppard, E. (2020) Manual vs Automated 68Ga-Radiolabelling—A Comparison of Optimized Processes. Journal of Labelled Compounds and Radiopharmaceuticals, 63, 162-173. https://doi.org/10.1002/jlcr.3821
[14]
Romero, E., Martínez, A., Oteo, M., Ibañez, M., Santos, M. and Morcillo, M.Á. (2020) Development and Long-Term Evaluation of a New 68Ge/68Ga Generator Based on Nano-SnO2 for PET Imaging. Scientific Reports, 10, Article No. 12756. https://doi.org/10.1038/s41598-020-69659-8
[15]
Nelson, B.J.B., Andersson, J.D., Wuest, F. and Spreckelmeyer, S. (2022) Good Practices for 68Ga Radiopharmaceutical Production. EJNMMI Radiopharmacy and Chemistry, 7, Article No. 27. https://doi.org/10.1186/s41181-022-00180-1
[16]
Carpenter, J.F., Chang, B.S., Garzon-Rodriguez, W. and Randolph, T.W. (2002) Rational Design of Stable Lyophilized Protein Formulations: Theory and Practice. In: Carpenter, J.F. and Manning, M.C., Eds., Rational Design of Stable Protein Formulations. Pharmaceutical Biotechnology, Vol. 13, Springer, 109-133. https://doi.org/10.1007/978-1-4615-0557-0_5
[17]
Shukla, S. (2011) Freeze Drying Process: A Review. International Journal of Pharmaceutical Sciences and Research, 2, 3061-3068. https://ijpsr.com/
[18]
Badal Tejedor, M., Fransson, J. and Millqvist-Fureby, A. (2020) Freeze-Dried Cake Structural and Physical Heterogeneity in Relation to Freeze-Drying Cycle Parameters. International Journal of Pharmaceutics, 590, Article 119891. https://doi.org/10.1016/j.ijpharm.2020.119891
[19]
Tang, X. and Pikal, M.J. (2004) Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice. Pharmaceutical Research, 21, 191-200. https://doi.org/10.1023/b:pham.0000016234.73023.75
[20]
Wang, W. (2000) Lyophilization and Development of Solid Protein Pharmaceuticals. International Journal of Pharmaceutics, 203, 1-60. https://doi.org/10.1016/s0378-5173(00)00423-3
[21]
Mukherjee, A., Pandey, U., Chakravarty, R., Sarma, H.D. and Dash, A. (2014) Development of Single Vial Kits for Preparation of 68Ga-Labelled Peptides for PET Imaging of Neuroendocrine Tumours. Molecular Imaging and Biology, 16, 550-557. https://doi.org/10.1007/s11307-014-0719-2
[22]
Tworowska, I., Ranganathan, D., Thamake, S., Delpassand, E., Mojtahedi, A., Schultz, M.K., et al. (2016) Radiosynthesis of Clinical Doses of 68Ga-DOTATATE (GaliomedixTM) and Validation of Organic-Matrix-Based 68Ge/68Ga Generators. Nuclear Medicine and Biology, 43, 19-26. https://doi.org/10.1016/j.nucmedbio.2015.08.004
[23]
Prince, D., Rossouw, D., Davids, C. and Rubow, S. (2017) Development and Evaluation of User-Friendly Single Vial DOTA-Peptide Kit Formulations, Specifically Designed for Radiolabelling with 68Ga from a Tin Dioxide 68Ge/68Ga Generator. Molecular Imaging and Biology, 19, 817-824. https://doi.org/10.1007/s11307-017-1077-7
[24]
European Directorate for the Quality of Medicines & HealthCare (2024) Gallium (68Ga) Chloride Solution for Radiolabelling. European Pharmacopoeia 11.0, 1273-1274.
[25]
Weineisen, M., Simecek, J., Schottelius, M., Schwaiger, M. and Wester, H. (2014) Synthesis and Preclinical Evaluation of DOTAGA-Conjugated PSMA Ligands for Functional Imaging and Endoradiotherapy of Prostate Cancer. EJNMMI Research, 4, Article No. 63. https://doi.org/10.1186/s13550-014-0063-1
[26]
Wieczorek Villas Boas, C.A., de Jesus Silva, J., Pereira Dias, L.A., Brandão Freire, M.R., Balieiro, L.M., Ferreira dos Santos, C.S., et al. (2022) In vitro and in vivo Response of PSMA-617 Radiolabeled with CA and NCA Lutetium-177. Applied Radiation and Isotopes, 180, Article 110064. https://doi.org/10.1016/j.apradiso.2021.110064
[27]
Kolhe, P., Amend, E. and Singh, S.K. (2009) Impact of Freezing on pH of Buffered Solutions and Consequences for Monoclonal Antibody Aggregation. Biotechnology Progress, 26, 727-733. https://doi.org/10.1002/btpr.377
[28]
Awotwe-Otoo, D., Agarabi, C., Read, E.K., Lute, S., Brorson, K.A., Khan, M.A., et al. (2013) Impact of Controlled Ice Nucleation on Process Performance and Quality Attributes of a Lyophilized Monoclonal Antibody. International Journal of Pharmaceutics, 450, 70-78. https://doi.org/10.1016/j.ijpharm.2013.04.041
